Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report)'s stock price crossed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of C$8.28 and traded as low as C$7.80. Fennec Pharmaceuticals shares last traded at C$7.90, with a volume of 1,652 shares trading hands.
Wall Street Analysts Forecast Growth
Separately, Stephens upgraded Fennec Pharmaceuticals to a "strong-buy" rating in a research note on Monday, November 18th.
Get Our Latest Research Report on Fennec Pharmaceuticals
Fennec Pharmaceuticals Stock Performance
The firm has a market cap of C$246.24 million, a PE ratio of 90.00 and a beta of 0.25. The company has a 50-day simple moving average of C$8.39 and a two-hundred day simple moving average of C$7.66. The company has a quick ratio of 10.17, a current ratio of 8.02 and a debt-to-equity ratio of 1,040.68.
Fennec Pharmaceuticals (TSE:FRX - Get Free Report) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported C($0.29) earnings per share for the quarter, missing analysts' consensus estimates of C($0.19) by C($0.10). Fennec Pharmaceuticals had a net margin of 5.59% and a negative return on equity of 1,005.59%. During the same quarter in the previous year, the firm earned ($0.09) earnings per share. As a group, equities research analysts forecast that Fennec Pharmaceuticals Inc. will post 0.6037736 earnings per share for the current year.
Insider Activity
In other news, Director Rostislav Christov Raykov purchased 25,000 shares of the stock in a transaction dated Friday, December 20th. The shares were purchased at an average cost of C$3.87 per share, with a total value of C$96,840.00. Also, Senior Officer Robert Christopher Andrade acquired 15,816 shares of Fennec Pharmaceuticals stock in a transaction that occurred on Monday, November 18th. The shares were purchased at an average cost of C$3.43 per share, with a total value of C$54,248.88. Insiders have acquired a total of 41,612 shares of company stock valued at $157,868 over the last quarter. Company insiders own 16.20% of the company's stock.
About Fennec Pharmaceuticals
(
Get Free Report)
Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
Featured Stories
Before you consider Fennec Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.
While Fennec Pharmaceuticals currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
